According to Zacks, “Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. “
Zacks Investment Research cut shares of Endologix (NASDAQ:ELGX) from a hold rating to a sell rating in a research note published on Monday.
A number of other equities research analysts have also issued reports on the stock. BTIG Research reissued a buy rating on shares of Endologix in a report on Tuesday, February 26th. ValuEngine raised shares of Endologix from a sell rating to a hold rating in a research report on Wednesday, January 2nd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $29.17.
Shares of ELGX opened at $6.76 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.55 and a debt-to-equity ratio of 4.38. Endologix has a 12-month low of $5.20 and a 12-month high of $67.20.
A number of hedge funds and other institutional investors have recently bought and sold shares of ELGX. Norges Bank acquired a new position in Endologix in the fourth quarter valued at about $545,000. Panagora Asset Management Inc. acquired a new position in Endologix in the third quarter valued at about $1,223,000. BlackRock Inc. lifted its position in Endologix by 8.9% in the fourth quarter. BlackRock Inc. now owns 6,208,597 shares of the medical instruments supplier’s stock valued at $4,446,000 after buying an additional 509,493 shares during the last quarter. Bank of America Corp DE lifted its position in Endologix by 880.9% in the fourth quarter. Bank of America Corp DE now owns 552,431 shares of the medical instruments supplier’s stock valued at $395,000 after buying an additional 496,113 shares during the last quarter. Finally, Stephens Inc. AR lifted its position in Endologix by 25.0% in the fourth quarter. Stephens Inc. AR now owns 2,398,414 shares of the medical instruments supplier’s stock valued at $1,717,000 after buying an additional 480,074 shares during the last quarter. 68.91% of the stock is currently owned by institutional investors.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
See Also: Rule of 72
Get a free copy of the Zacks research report on Endologix (ELGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com